Autolus Therapeutics PLC Sponsored ADR - Hold
Zacks' proprietary data indicates that Autolus Therapeutics PLC Sponsored ADR is currently rated as a Zacks Rank 3 and we are expecting an inline return from the AUTL shares relative to the market in the next few months. In addition, Autolus Therapeutics PLC Sponsored ADR has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Autolus Therapeutics PLC Sponsored ADR may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of AUTL, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Style Scorecard
Value Scorecard
Growth Scorecard
Momentum Scorecard
Value Score | AUTL: F | Industry [X] | HUMA: F | IGMS: F | APLM: F |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 2 | 3 | |
VGM Score | F | F | F | F | |
Cash/Price | 0.67 | 0.44 | 0.14 | 0.52 | 2.16 |
EV/EBITDA | -2.37 | -1.10 | -7.63 | -1.11 | 0.12 |
PEG Ratio | NA | 2.26 | NA | NA | NA |
Price/Book (P/B) | 1.94 | 2.16 | 31.83 | 3.52 | 0.41 |
Price/Cash Flow (P/CF) | NA | 16.71 | NA | NA | NA |
P/E (F1) | NA | 24.76 | NA | NA | NA |
Price/Sales (P/S) | NA | 6.56 | NA | 270.30 | NA |
Earnings Yield | -18.35% | -27.13% | -13.59% | -23.96% | -325.00% |
Debt/Equity | 0.00 | 0.00 | 0.61 | 0.00 | 0.00 |
Cash Flow ($/share) | -1.16 | -1.53 | -0.85 | -4.21 | -1.98 |
Growth Score | AUTL: F | Industry [X] | HUMA: D | IGMS: D | APLM: F |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 2 | 3 | |
VGM Score | F | F | F | F | |
Hist. EPS Growth | NA | 2.51% | NA% | NA% | NA% |
Proj. EPS Growth | 35.28% | 19.19% | 10.98% | 50.99% | 71.98% |
Curr. Cash Flow Growth | 42.71% | -2.92% | 13.35% | 13.57% | -28.37% |
Hist. Cash Flow Growth | NA | 2.50% | NA% | NA% | NA% |
Current Ratio | 18.29 | 4.63 | 8.37 | 7.98 | 2.95 |
Debt/Capital | 0.00% | 0.00% | 37.74% | 0.00% | 0.00% |
Net Margin | NA | -220.28% | NA% | -11,255.25% | NA% |
Return on Equity | -80.21% | -61.83% | -306.81% | -108.07% | NA% |
Sales/Assets | NA | 0.22 | NA | 0.00 | NA |
Proj. Sales Growth (F1/F0) | 1,237.46% | 1.36% | NA% | 2,399.20% | 0.00% |
Momentum Score | AUTL: D | Industry [X] | HUMA: C | IGMS: D | APLM: B |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 2 | 3 | |
VGM Score | F | F | F | F | |
Daily Price Chg | 2.41% | 0.93% | 8.37% | 3.66% | -99,999.00% |
1 Week Price Chg | 23.19% | 7.48% | 32.64% | 53.50% | 2.30% |
4 Week Price Chg | -5.56% | 0.72% | -0.85% | 32.42% | -2.69% |
12 Week Price Chg | -5.97% | -1.58% | 88.92% | 33.89% | -58.56% |
52 Week Price Chg | 72.76% | -27.04% | 130.69% | -3.60% | -96.50% |
20 Day Average Volume | 1,525,739 | 214,396 | 3,476,088 | 263,796 | 290,170 |
(F1) EPS Est. Wkly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
(F1) EPS Est. Mthly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
(F1) EPS Est. Qtrly Chg | -9.13% | 1.06% | -6.13% | 28.61% | 0.00% |
(Q1) EPS Est. Mthly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Zacks News for AUTL
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services